Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort
Mucci, L. A.
Stark, J. R.
Eisenstein, A. S.
Kantoff, P. W.
Rubin, M. A.
MetadataShow full item record
CitationMucci, L. A., Y. Pawitan, F. Demichelis, K. Fall, J. R. Stark, H.-O. Adami, S.-O. Andersson, et al. 2008. “Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort.” Cancer Epidemiology Biomarkers & Prevention 17 (1): 249–51. https://doi.org/10.1158/1055-9965.epi-07-0722.
AbstractTumor molecular markers hold promise to distinguish potentially lethal from indolent prostate cancer and to guide treatment choices. A previous study identified a nine-gene molecular signature in tumors associated with prostate-specific antigen relapse after prostatectomy. We examined this molecular model in relation to prostate cancer death among 172 men with initially localized disease. We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41292882
- SPH Scholarly Articles